Source:http://linkedlifedata.com/resource/pubmed/id/10489210
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
1999-10-19
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0931-0509
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2079-81
|
pubmed:dateRevised |
2005-11-16
|
pubmed:meshHeading |
pubmed-meshheading:10489210-Antiviral Agents,
pubmed-meshheading:10489210-Drug Combinations,
pubmed-meshheading:10489210-Hepatitis C,
pubmed-meshheading:10489210-Humans,
pubmed-meshheading:10489210-Interferon-alpha,
pubmed-meshheading:10489210-Kidney Failure, Chronic,
pubmed-meshheading:10489210-Nephrology,
pubmed-meshheading:10489210-Ribavirin
|
pubmed:year |
1999
|
pubmed:articleTitle |
Combination of interferon alpha and ribavirin in the treatment of hepatitis C: implications for the clinical nephrologist.
|
pubmed:publicationType |
Editorial,
Review
|